Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rivastigmine tartrate (SDZ-ENA 713) is a carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 47.00 | |
50 mg | In stock | $ 55.00 | |
100 mg | In stock | $ 81.00 | |
200 mg | In stock | $ 108.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 58.00 |
Description | Rivastigmine tartrate (SDZ-ENA 713) is a carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE. |
Targets&IC50 | AChR:5.5 μM |
Synonyms | SDZ-ENA 713, ENA 713 |
Molecular Weight | 400.43 |
Formula | C14H22N2O2·C4H6O6 |
CAS No. | 129101-54-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 74 mg/mL (184.8 mM)
DMSO: 39 mg/mL (97.4 mM)
H2O: 73 mg/mL (182.3 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rivastigmine tartrate 129101-54-8 Neuroscience AChR AChE ENA-713 BBB cholinesterase acetylcholinesteras SDZ-ENA 713 BChE disease orally butyrylcholinesterase Inhibitor Alzheimer's Parkinson's SDZ-ENA-713 ENA 713 Cholinesterase (ChE) ENA713 ChE Rivastigmine Tartrate SDZ-ENA713 Rivastigmine cholinergic inhibit parasympathomimetic inhibitor